<DOC>
	<DOCNO>NCT02673996</DOCNO>
	<brief_summary>Objective : In pilot study , test hypothesis patient POTS ( age 18-60 year ) high percentage functional antibody adrenergic receptor compare control subject without POTS .</brief_summary>
	<brief_title>POTS Adrenergic Ab ( CIHR Aims # 1 &amp; 2 )</brief_title>
	<detailed_description>Background &amp; Rationale : Postural Tachycardia Syndrome ( POTS ) chronic state orthostatic tachycardia ( &gt; 30 bpm increment lie stand ) typical symptom worse standing , relieve lying . Typical orthostatic symptom include palpitation , lightheadedness , chest pain , dyspnea , tremulousness , blur vision mental clouding . POTS often occur young individual female predominance ( 4-5 fold ) . Using RAND36 quality life ( QOL ) tool , show POTS patient low quality life ( QOL ) score healthy subject physical ( 26±9 vs. 54±6 ; P &lt; 0.0001 ) mental health domain ( 43±11 vs. 52±10 ; P &lt; 0.0001 ) . These QOL score similar score chronic obstructive pulmonary disease congestive heart failure . In collaboration Kem/Yu lab ( Oklahoma University ) , investigator seek determine whether POTS patient functionally significant adrenergic receptor ( AR ) Abs . Samples 14 POTS patient ( include 7 blind , well-characterized sample Vanderbilt ) 10 healthy control subject . Using rat cremaster artery assay , sera/immunoglobulin ( IgG ) POTS patient demonstrate significantly great arteriolar contractile activity ( 69±3 % baseline vessel diameter ) compare control subject ( 91±1 % baseline ; P &lt; 0.001 ) . This contractility suppress prazosin , α1-AR blocker . With addition POTS serum , phenylephrine dose-response curve shift right . In word , high dose phenylephrine require achieve degree vasoconstriction , suggest α1-AR Ab actually partial-agonist/antagonist . Using cell-based cyclic AMP ( cAMP ) reporter assay , POTS sera dose-dependent β1-AR activation ( max : +30±3 % buffer baseline ) compare control serum ( -1±2 % buffer baseline ; P &lt; 0.001 ) , 7/14 POTS patient ( control subject ) elevate β2-AR activation . The excessive β1-AR activation could block propranolol . With addition POTS serum , isoproterenol dose-response curve shift left ( low isoproterenol dose require achieve receptor activation presence POTS serum ) . These data suggest β1-AR Ab actually straight agonist . Big Picture : While excite , data obtain 14 POTS patient . In protocol ( Aim # 1 ; REB15-2434 ) , investigator study large cohort POTS patient control subject order well sense true prevalence antibody , determine association autoimmune illness , see relate patient-reported onset illness . In addition , investigator seek see whether physiologically significant intact human vivo ( Aim # 2 ) . The investigator propose perform dose response study phenylephrine isoproterenol POTS patient control subject blood pressure ( BP ) heart rate ( HR ) output metric determine different POTS patient control subject , importantly , base auto-antibody vitro activity . Specifically , investigator give series injection small dos phenylephrine monitor HR continuous BP . After injection , investigator note peak BP increase monitor patient BP return baseline . The investigator give incrementally large dos endpoint achieve . The endpoint low test dose phenylephrine increase systolic BP &gt; 25 mmHg ( PHE-PD25 ) . investigator repeat process small dose isoproterenol monitoring . After injection , investigator note peak HR increase monitor patient HR return baseline . The investigator give incrementally large dos endpoint achieve . The endpoint low test dose isoproterenol increase HR &gt; 25 bpm ( ISO-PD25 ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Isoproterenol</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<criteria>Patients previously diagnose POTS Control subject ( patient diagnose POTS ) Age 18 60 year Males Females ( Give &gt; 80 % POTS patient female , attempt enroll similar percentage female control subject ) Able willing provide consent Smokers Overt cause postural tachycardia , i.e. , acute dehydration Significant cardiovascular , pulmonary , hepatic , hematological disease history prior test Highly trained athlete Subjects somatization severe anxiety symptom exclude Use drospirenone ( spironolactone analogue ) contain oral contraceptive agent Hypertension define supine rest BP &gt; 145/95 mmHg medication need antihypertensive medication Other factor investigator 's opinion would prevent participant complete protocol , include poor compliance previous study unpredictable schedule Unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>antibody</keyword>
	<keyword>autoimmune</keyword>
	<keyword>adrenergic</keyword>
	<keyword>autonomic</keyword>
</DOC>